Allergan Gets FDA Nod for Lip Augmentation DrugBy
The US Food and Drug Administration has approved Allergan’s Juvederm Volbella XC for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21.
Juvederm Volbella XC is formulated with Vycross 2 a proprietary filler technology from Allergan, which yields smooth products that have been engineered to address specific patient concerns such as lip fullness, age-related volume loss in the cheek area, or perioral rhytids.
Juvederm Volbella XC was first approved in Europe in 2011. Currently, it is distributed in more than 70 countries, including markets in Europe, Latin America, Middle East, Asia Pacific, and Canada.
It will be available in the US in October 2016.